"The voice of oncology in Massachusetts."

AstraZeneca's Imjudo (tremelimumab-actl) Has Been Assigned a Unique HCPCS Code and ASP by CMS

July 18, 2023 1:47 PM | Katy Monaco (Administrator)

AstraZeneca is pleased to announce that IMJUDO® (tremelimumab-actl) has been assigned a unique Healthcare Common Procedure Coding System (HCPCS) code and Average Sales Price (ASP) by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after July 1, 2023, the following code (J9347) can be used by providers to identify IMJUDO when billing across settings of care as noted in the (2023) Alpha-Numeric HCPCS file.  Read More.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software